IL17A and inflammatory breast carcinoma: Another important finding is that tumor Sdc-1 silencing significantly induced elevated proportion of the Th17 (IL-17+CD4+) subset among CD4+ T cells of non-IBC patients when stimulated by the secretome of Sdc-1-silenced SUM-149 cells and under direct co-culture, conditions as compared to negative controls.